Citigroup’s Cytokinetics CYTK Stock Holding History

Citigroup’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60,000	Closed	-$3.81M	–	6031
2025 Q4	$3.81M	Buy	60,000 +35,000	+140%	+$2.18M	﹤0.01%	2215
2025 Q3	$1.37M	Sell	25,000 -5,000	-17%	-$206K	﹤0.01%	2959
2025 Q2	$991K	Sell	30,000 -65,500	-69%	-$2.28M	﹤0.01%	3201
2025 Q1	$3.84M	Sell	95,500 -1,300	-1%	-$59.7K	﹤0.01%	2152
2024 Q4	$4.55M	Sell	96,800 -700	-0.7%	-$36.4K	﹤0.01%	2060
2024 Q3	$5.15M	Buy	+97,500	New	+$5.43M	﹤0.01%	1820
2024 Q1	–	Sell	-30,000	Closed	-$2.5M	–	5676
2023 Q4	$2.5M	Buy	+30,000	New	+$1.09M	﹤0.01%	2053
2023 Q3	–	Sell	-55,000	Closed	-$1.79M	–	5692
2023 Q2	$1.79M	Sell	55,000 -29,400	-35%	-$1.09M	﹤0.01%	2316
2023 Q1	$2.97M	Buy	84,400 +54,400	+181%	+$2.22M	﹤0.01%	1767
2022 Q4	$1.37M	Buy	+30,000	New	+$1.29M	﹤0.01%	2336
2022 Q3	–	Sell	-20,000	Closed	-$786K	–	5917
2022 Q2	$786K	Buy	+20,000	New	+$805K	﹤0.01%	2871

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's CYTK Position: Q1 2026 in Review

Citigroup increased its Cytokinetics (CYTK) stake by 144% in Q1 2026, buying an estimated $9.35M and bringing the position to 249,243 shares worth $16.4M. The position accounts for 0.01% of the portfolio, ranked #1180.

Citigroup first reported a position in CYTK in Q2 2013 and has held it in 52 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Citigroup held 249,243 shares of Cytokinetics worth $16.4M as of Q1 2026.
Citigroup bought 147,142 Cytokinetics shares in Q1 2026, an estimated $9.35M.
Cytokinetics made up 0.01% of Citigroup's portfolio in Q1 2026, its #1180 holding.
Citigroup first reported a position in Cytokinetics in Q2 2013 and has held it in 52 quarters since.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.